Short-Term Prognosis Evaluation of Transient Ischemic Attack Patients Using ABCD2 Score

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Capital Medical University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Beijing Anzhen Hospital
Information provided by:
Capital Medical University
ClinicalTrials.gov Identifier:
NCT00553241
First received: November 2, 2007
Last updated: January 29, 2009
Last verified: January 2009
  Purpose

The purpose of this study is to determine whether the ABCD2 score can be used in patients with transient ischemic attack, admitted to Beijing anzhen hospital, to evaluate the prognosis, risk factor of those patients.


Condition
Ischemic Attack, Transient

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase 1 of Clinical Trial of Risk Factor, Prognosis, Imaging and Standard Management of Transient Ischemic Attack.

Resource links provided by NLM:


Further study details as provided by Capital Medical University:

Primary Outcome Measures:
  • end points are defined as follow: transient ischemic attack, stroke, angina, myocardial infraction, peripheral vascular disease, intracerebral hemorrhage and other vascular death. [ Time Frame: two year ] [ Designated as safety issue: No ]

Estimated Enrollment: 1
Study Start Date: June 2007
Estimated Study Completion Date: January 2009
Groups/Cohorts
1

Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China

Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour.


Detailed Description:

The feasibility of risk stratification of patients with acute transient ischemic attack admitted to Beijing anzhen hospital by the ABCD2 score system is yet to be determined. The aim of this paper was to evaluate and validate the short-term prognosis of TIA patients in Peking area using this new score system.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients diagnosed with transient will be enrolled in this study

Criteria

Inclusion Criteria:

  • Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour.
  • Magnetic resonance imaging negative on DWI(no fresh infarction).
  • Old infarction or not the criminal infarction.

Exclusion Criteria:

  • Patients with hemorrhage stroke were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00553241

Locations
China
Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Recruiting
Beijing, China, 100029
Contact: li F Wang       wlfsjnk@163.com   
Principal Investigator: Bi Qi         
Sponsors and Collaborators
Capital Medical University
Beijing Anzhen Hospital
Investigators
Study Chair: Qi Bi Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University
  More Information

Publications:

Responsible Party: Beijing Anzhen Hospital, Capital Medical University
ClinicalTrials.gov Identifier: NCT00553241     History of Changes
Other Study ID Numbers: 2007020
Study First Received: November 2, 2007
Last Updated: January 29, 2009
Health Authority: China: Ministry of Health

Keywords provided by Capital Medical University:
TIA
prognosis
evaluation
management

Additional relevant MeSH terms:
Ischemic Attack, Transient
Ischemia
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 19, 2014